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Background: Stable coronary artery disease (CAD) is the most frequent cause of death in western country. Elevated serum YKL-40 is a short-
term risk factor for myocardial infarction (MI), cardiovascular and all-cause mortality in patients with stable CAD.We investigated whether the 
inflammatory biomarker YKL-40, corrected for high-sensitivity C-reactive protein (hs-CRP) and N-terminal-pro-B natriuretic peptide (NT-proBNP), 
could be used as an independent long-term predictor of all-cause death in patients with stable CAD. 
Methods: Serum YKL-40, hs-CRP and NT-proBNP were measured in 4372 patients with stable CAD included in the Claricor trial and death was 
registered in a 6-years follow-up period. 
Results: 4265 (96.8% out of the 4372) patients had blood samples available for serum YKL-40, hs-CRP and NT-proBNP determination leaving 
107 with one or more missing. Difference between these two groups was not significant. Serum YKL-40 (transformed as ln(max(83, YKL-40/μg/L)) 
was significantly associated with all-cause mortality [hazard ratio (HR) =1.55, 95% confidence interval (CI)=1.39-1.73, p<0.001] after multivariable 
adjustment for treatment with Clarithromycin, age, sex, hypertension, diabetes, smoking status, previous MI, diuretics, digoxin, statin. After additional 
adjustment for ln(hs-CRP) and ln(NT-proBNP) serum YKL-40 still contributed significantly to prediction of all-cause mortality [HR=1.38, 95%CI=1.21-
1.53, p<0.001].
Conclusions: Increased serum YKL-40 is an independent predictor of long-term mortality in patients with stable CAD. Serum YKL-40 can potentially 
be used to monitor outcome in patients with CAD and maybe also for monitoring clinical treatment.
